Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms

Summary

Ractigen Therapeutics closed a $31 million financing round led by Guozhong Capital to advance its clinical-stage saRNA pipeline, including Phase 2 development for RAG-01 and RAG-17, and expansion of extrahepatic RNA delivery technologies.